Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions

Drug repurposing appears to offer an attractive alternative in finding new anticancer agents. Their applicability seems to have multiple benefits, among which are the potential of immediate efficacy assessment in clinical trials and the existence of patient safety and tolerability evidence. Neverthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sertedaki, Eleni, Kotsinas, Athanassios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291122/
https://www.ncbi.nlm.nih.gov/pubmed/32414147
http://dx.doi.org/10.3390/cells9051210
_version_ 1783545836010995712
author Sertedaki, Eleni
Kotsinas, Athanassios
author_facet Sertedaki, Eleni
Kotsinas, Athanassios
author_sort Sertedaki, Eleni
collection PubMed
description Drug repurposing appears to offer an attractive alternative in finding new anticancer agents. Their applicability seems to have multiple benefits, among which are the potential of immediate efficacy assessment in clinical trials and the existence of patient safety and tolerability evidence. Nevertheless, their effective application in terms of tumor-type targeting requires accurate knowledge of their exact mechanism of action. In this review, we present such a successful drug, namely Disulfiram (commercially known as Antabuse), and discuss its recently uncovered mode of anticancer action through DNA damage.
format Online
Article
Text
id pubmed-7291122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72911222020-06-17 Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions Sertedaki, Eleni Kotsinas, Athanassios Cells Editorial Drug repurposing appears to offer an attractive alternative in finding new anticancer agents. Their applicability seems to have multiple benefits, among which are the potential of immediate efficacy assessment in clinical trials and the existence of patient safety and tolerability evidence. Nevertheless, their effective application in terms of tumor-type targeting requires accurate knowledge of their exact mechanism of action. In this review, we present such a successful drug, namely Disulfiram (commercially known as Antabuse), and discuss its recently uncovered mode of anticancer action through DNA damage. MDPI 2020-05-13 /pmc/articles/PMC7291122/ /pubmed/32414147 http://dx.doi.org/10.3390/cells9051210 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Sertedaki, Eleni
Kotsinas, Athanassios
Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title_full Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title_fullStr Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title_full_unstemmed Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title_short Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions
title_sort drug repurposing and dna damage in cancer treatment: facts and misconceptions
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291122/
https://www.ncbi.nlm.nih.gov/pubmed/32414147
http://dx.doi.org/10.3390/cells9051210
work_keys_str_mv AT sertedakieleni drugrepurposinganddnadamageincancertreatmentfactsandmisconceptions
AT kotsinasathanassios drugrepurposinganddnadamageincancertreatmentfactsandmisconceptions

Ejemplares similares